- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.05. | EMA recommends approvals for both oral and high-dose pen of Wegovy | ||
| 26.05. | Eli Lilly to buy trio of vaccine developers in $3.8bn outlay | ||
| 26.05. | University of Edinburgh develops cell therapy for liver disease | ||
| 26.05. | Pierre Fabre's Braftovi gains CHMP positive opinion for mCRC | ||
| 25.05. | AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC | ||
| 22.05. | CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati | ||
| 22.05. | European STI cases reach record high amid testing and prevention gaps | ||
| 22.05. | Gilead Sciences acquires Tubulis for $5bn | ||
| 22.05. | Concept Life Sciences and OpenBench partner on drug discovery services | ||
| 21.05. | Gilead teams up with WHO again to eliminate parasitic tropical disease | ||
| 21.05. | Eli Lilly maintains M&A streak with $202m Engage Bio buyout | ||
| 21.05. | FUJIFILM opens new iPSC facility in Madison, US | ||
| 21.05. | BMS and Anthropic collaborate for Claude implementation | ||
| 20.05. | Investment giants join forces to form largest healthcare firm on the globe | ||
| 20.05. | Clinical Trials Day 2026: 'Research Rising' theme reflected in Q1 study growth | ||
| 20.05. | Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict | ||
| 20.05. | QIAGEN and NVIDIA partner on AI drug discovery | ||
| 20.05. | SERB signs agreement to acquire Idefirix rights for $133.6m | ||
| 19.05. | UK government bolsters antiviral supply for hantavirus | ||
| 19.05. | VERTANICAL's VER-01 gains FDA breakthrough status for low back pain | ||
| 19.05. | Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates | ||
| 18.05. | Vaccine void means current Ebola outbreak declared international emergency | ||
| 18.05. | Tracy Beth Høeg ousted from FDA in wider senior leadership shakeup | ||
| 18.05. | Japan's MHLW approves Boehringer's Jascayd for IPF and PPF | ||
| 18.05. | FDA approves Enhertu for two HER2-positive early breast cancer indications |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.